Cerenovus, part of Johnson & Johnson Medical Devices Companies, has announced the European launch of Cerenovus Nimbus designed to remove tough clots for successful revascularisation in patients with acute ischemic stroke caused by a large vessel occlusion.
Ischemic strokes account for 85% of all strokes and up to 46% are caused by a large vessel occlusion (LVO). Strokes caused by LVO have devasting consequences – they are responsible for 60% of patient dependency due to disability and more than 90% of mortality.
Mechanical thrombectomy (MT), a minimally invasive procedure, is the recommended treatment option for acute ischemic stroke; however, successful recanalisation is not achieved within three passes or not at all, in approximately 25% of thrombectomy cases due, in some cases, to the inability to remove a tough clot. Each attempt is associated with an increased risk of vessel injury and potential impact on clinical outcomes.
Cerenovus Nimbus is designed to remove tough clot. The device is designed with two different design features to maximise tough clot removal: a proximal spiral section and distal barrel section. The spiral section is specifically designed to maximise blood vessel lumen coverage and device-clot interaction, providing engagement with the clot and facilitate dislodgement of resistant clots. Through this unique design Nimbus has the potential to improve reperfusion rates and reduce the number of passes required in tough clot cases, which may lead to improvement in patient outcomes.
Dr. Hannes Nordmeyer, Radprax Neurocentre, Solingen, Germany, said: “The performance of MT devices varies according to the composition and characteristics of the occluding thrombus and we know that retrieving fibrin rich clots and restoring flow is challenging. Having a device specifically designed to retrieve tough clots for successful revascularisation may improve clinical outcomes and advance stroke treatment.”
Nimbus is the latest addition to join Cerenovus Stroke Solutions - a suite of technologies designed with compatibility in mind to help physicians perform mechanical thrombectomy procedure. Launched at ESMINT 2020, Cerenovus Stroke Solutions, includes Cerebase DA Guide Sheath, Embovac Catheter and Embotrap III Revascularisation Devices.
Mark Dickinson, worldwide president, Cerenovus, said: “Using the research from our Neuro Thromboembolic Initiative (NTI), we have been able to address the critical unmet clinical need of tough clot retrieval. Nimbus gives physicians an additional treatment option for tough clot composition. Our latest innovation demonstrates our commitment to ensuring physicians have the most advanced tools in their hands to change the trajectory of stroke.”
Strokes are the second leading cause of death globally, with estimates suggesting that by 2035 the number of stroke deaths across Europe will increase by 45%. Over half of stroke survivors become chronically disabled, jeopardising their quality of life and placing an economic burden on healthcare systems. In the European Union alone the total cost of stroke was estimated at €45 billion in 2015.
